NDAORALTABLET
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
established.
Pharmacologic Class:
Pyridone
Indications (1)
Clinical Trials (5)
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
Started Mar 2026
20 enrolled
Idiopathic Pulmonary Fibrosis
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
Started Jun 2025
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
Started Nov 2023
14 enrolled
Healthy
Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects
Started Jul 2021
58 enrolled
Healthy
Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease
Started Oct 2020
200 enrolled
Chronic Kidney Disease
Loss of Exclusivity
LOE Date
Mar 28, 2037
134 months away
Patent Expiry
Mar 28, 2037